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ABSTRACT
BMP7 is a growth factor playing pro- or anti-oncogenic roles in cancer in a cell 
type-dependent manner. We previously reported that the BMP7 gene is overexpressed 
in pheochromocytomas (PCCs) developing in MENX-affected rats and human patients. 
Here, analyzing a large cohort of PCC patients, we found that 72% of cases showed 
elevated levels of the BMP7 protein. To elucidate the role of BMP7 in PCC, we modulated 
its levels in PCC cell lines (overexpression in PC12, knockdown in MPC and MTT cells) 
and conducted functional assays. Active BMP signaling promoted cell proliferation, 
migration, and invasion, and sustained survival of MENX rat primary PCC cells. In 
PCC, BMP7 signals through the PI3K/AKT/mTOR pathway and causes integrin β1 up-
regulation. Silencing integrin β1 in PC12 cells suppressed BMP7-mediated oncogenic 
features. Treatment of MTT cells with DMH1, a novel BMP antagonist, suppressed 
proliferation and migration. To verify the clinical applicability of our findings, we 
evaluated a dual PI3K/mTOR inhibitor (NVP-BEZ235) in MENX-affected rats in vivo. 
PCCs treated with NVP-BEZ235 had decreased proliferation and integrin β1 levels, 
and higher apoptosis. Altogether, BMP7 activates pro-oncogenic pathways in PCC. 
Downstream effectors of BMP7-mediated signaling may represent novel targets for 
treating progressive/inoperable PCC, still orphan of effective therapy.
INTRODUCTION
Pheochromocytomas (PCCs) are tumors arising 
from neural crest-derived chromaffin cells of the adrenal 
medulla and sympathetic ganglia (the latter referred to as 
paragangliomas, PGLs). PCCs/PGLs occur sporadically 
or as a result of an inherited germline mutation in one of 
at least 12 genes (35%–40% of cases), including VHL, 
NF1, RET, SDHA, SDHB, SDHC, SDHD, SDHAF2, 
HIF2α, KIF1Bβ, TMEM127, MAX and FH [1]. In contrast 
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to familial PCC/PGL, less is known about the somatic 
mechanisms driving the more frequent sporadic tumors. 
Recently, using an integrative genomics approach, 
common alterations were discovered in sporadic PCC that 
now await functional validation [2, 3].
Transcriptome analyzes have determined that 
gene expression signatures of human PCCs reflect the 
underlying driver mutation [4,5]. Specifically, PCCs and 
PGLs can be divided into two main clusters, designated as 
Cluster 1 and Cluster 2; Cluster 1 tumors are associated 
with germline mutations in VHL, SDHx, and probably 
HIF2α and FH genes, and Cluster 2 tumors are associated 
with mutations in NF1, RET, KIF1Bβ, and TMEM127 [1]. 
Sporadic PCCs mainly group in Cluster 2.
Although usually benign, approximately 10–15% 
of PCC cases are considered malignant on the basis 
of the presence of distant metastases and have a 5-year 
survival rate of <50% [6]. Surgery remains the first-line 
therapy for patients with localized disease or with isolated 
and resectable distant metastases [7]. For patients with 
disseminated tumor spread, extensive local invasion, or 
recurrence, systemic conventional chemotherapy has 
been tested without clear benefit on overall survival. 
Radiotherapy with the radiopharmaceutical 131I-meta-
iodobenzylguanidine (131I-MIBG) was shown to have 
positive therapeutic effects, but tumor regression occurred 
in only 30% of patients [8]. The tyrosine kinase inhibitor 
sunitinib has shown some efficacy in patients with a 
progressive disease [9], whereas the mTOR inhibitor 
everolimus exhibited low efficacy [10, 11]. Taken 
together, there is a considerable clinical need for more 
effective therapies against aggressive/malignant PCC; 
elucidating the molecular mechanisms involved in PCC 
tumorigenesis will be instrumental in identifying targets 
for such therapies.
Rats affected by the MENX multiple endocrine 
neoplasia syndrome develop bilateral PCCs with complete 
penetrance [12]. The tumors show progression from 
hyperplasia (4 months of age) to tumors (7–8 months 
of age) with time. Rat PCCs share similarities with 
their human counterparts in terms of histopathological 
features [13, 14], gene copy number variations [13], 
expression signatures [14], and uptake of radiolabeled 
tracers for imaging [15, 16]. The rat tumors show elevated 
proliferation rates (average 11.3%, range 3.7% to 16.7%) 
[15], thus mostly resembling human aggressive PCCs. 
Despite these high proliferation rates, no metastases of 
rat pheochromocytomas have been so far documented, 
probably due to the short life span of MENX rats [17]. 
To elucidate the molecular pathogenesis of PCC, 
we previously performed transcriptome analyzes of 
adrenomedullary hyperplasia and tumors from MENX-
affected rats. These studies identified the Bmp7 gene, never 
before associated with adrenomedullary tumorigenesis, as 
being significantly overexpressed in rat hyperplastic and 
neoplastic lesions versus normal adrenal medulla [14]. 
Bmp7 was already up-regulated in the adrenal medulla 
of 1-month-old mutant rats before pathological changes 
occur. Importantly, the BMP7 gene was also found to be 
up-regulated in 88% of human sporadic PCCs and 69% of 
the familial cases [14].
BMP7 (bone morphogenic protein 7) belongs to 
the transforming growth factor β (TGFβ) superfamily of 
secreted growth factors [18]. Besides a role in embryonic 
development, differentiation, and organogenesis, 
BMPs were recently implicated in regulating growth, 
migration, and apoptosis of cancer cells [19–21]. BMPs 
bind to types I and II transmembrane serin/threonine 
kinase receptors (BMPR-I or BMPR-II), which dimerize 
upon ligand binding, and the constitutively activated 
BMPR-II phosphorylates BMPR-I [22]. In the canonical 
BMP pathway, BMPRI phosphorylates receptor-
associated SMAD transcription factors [SMADs 1, 5, and 
8 (mouse)/9 (human)], which then bind to the common 
mediator SMAD4 and translocate into the nucleus [22], 
where these complexes bind to the DNA and regulate 
target gene transcription [23].
In human cancers, BMPs exhibit pro- or anti-
carcinogenic functions depending on the cell/tissue 
type, dosage, and micro-environment [24]. Although 
the functional significance of BMP7 has been studied in 
several tumors, including breast, colorectal, gastric, and 
prostate carcinomas [25–28], its role in adrenomedullary 
tumorigenesis has not yet been explored. Using a large 
cohort of well-characterized PCC/PGL patients, we here 
confirmed that the BMP7 protein is highly expressed 
in >70% of tumors; this correlates with extra-adrenal 
location and tumor size. We demonstrated that endogenous 
BMP7 overexpression promotes PCC cell proliferation, 
migration, and invasion and identified the PI3K/AKT/
mTOR pathway and integrin β1 as downstream effectors 
of active BMP signaling. Proof-of-principle studies using 
a specific BMP antagonist (in vitro) and a PI3K/mTOR 
inhibitor (in vivo) revealed that targeting BMP7-mediated 
pathways could be an effective strategy to treat PCCs.
RESULTS
Bmp7 expression in rat PCCs
We investigated whether Bmp7 transcript over-
expression, previously observed in MENX-associated 
rat PCCs [14], translates into increased levels of the 
encoded protein. By immunohistochemistry (IHC) and 
immunofluorescence (IF), we could confirm that Bmp7 
protein levels and those of its canonical downstream 
targets [i.e., phosphorylated (P)-Smad1/5/8] were elevated 
in the tumors of mutant animals compared with the adrenal 
medulla of wild-type animals (Figure 1A). Concordantly, 
circulating Bmp7 protein was significantly elevated in the 
peripheral blood of mutant when compared with wild-type 
animals (P = 0.0006) (Figure 1B). Collectively, these data 
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demonstrate that the Bmp7 protein is expressed at a high 
level in rat PCCs and is secreted.
BMP7 expression in human PCCs
Similar to the rat tumors, human sporadic and 
familial PCCs also overexpress the BMP7 gene [14]. 
Following preliminary immunohistochemical studies on 
10 human primary PCCs, we extended our analysis to a 
large and well-characterized cohort of 208 PCCs/PGLs 
spotted on tissue microarrays (TMAs). A total of 184 
tumor samples (150 PCCs and 34 PGLs) satisfied our 
inclusion criteria (see Material and Methods). IHC was 
performed and TMAs were scored for staining intensity. 
The anti-BMP7 antibody we used has a reported 25% 
cross-reactivity with BMP6 and no cross-reactivity with 
other BMPs. However, given that the BMP6 gene was 
found to be expressed at the limit of detection in a series 
of 10 frozen human PCCs by TaqMan (data not shown), 
the signal observed by IHC is specific for BMP7. In our 
cohort, 72% of the tumors displayed moderate (++) to 
strong (+++) immunoreactivity for BMP7 (Figure 2A–2D). 
We then studied the possible correlations between BMP7 
levels and either clinical parameters of the patients or 
tumor characteristics. No association between BMP7 
expression and gender, age, plasma catecholamines, or 
Figure 1: Expression of Bmp7 in rat PCC and its secretion. A. IHC or IF on adrenal medullary tissue from wild-type and mutant 
rats was performed using a rat anti-BMP7 antibody or an anti-P-Smad1/5/8 antibody, respectively. These tissues are representative of five 
tissues per animal group. Original magnification: 400× B. Plasma Bmp7 levels were measured in seven MENX mutant rats and seven wild-
type rats fasted for 12 h. Measurements were performed using a rat Bmp7 ELISA-KIT. ***, P < 0.001.
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chromogranin A levels was evident. In contrast, we found 
that 88% of the PGLs, but only 68% of PCCs, exhibit an 
elevated BMP7 expression (P = 0.02, Figure 2E). BMP7 
levels were high (++/+++) in 93% of tumors bigger 
than 8 cm in diameter (large), but only in 56% of the 
tumors smaller than 3 cm in diameter (small, P = 0.018, 
Figure 2F). Concerning the underlying predisposing 
mutation, we found that 92% of Cluster-1 tumors show 
high BMP7 levels as opposed to 74% of Cluster-2 tumors; 
however, this difference was not statistically significant 
(Figure 2G). In our series, 11 cases were malignant and 
nine of them showed high BMP7 expression, suggesting 
a trend for higher BMP7 levels in malignant tumors 
(Figure 2H).
Thus, in human PCCs, BMP7 is highly expressed 
and its levels positively associate with tumor size and 
origin (extra-adrenal).
BMP7 promotes proliferation of PCC cell lines 
and the viability of primary rat PCC cells
As no data were available on the possible role of 
Bmp7 in PCC, we performed in vitro functional assays. We 
first employed as experimental model the PC12 cell line, 
established from a rat PCC [29]. Consistent with published data 
[30], PC12 cells were found to express BMP receptors, thereby 
representing a suitable model to study autocrine/paracrine 
effects of endogenous BMP signaling (Supplementary 
Figure S1). PC12 cells express the endogenous Bmp7 gene at 
relatively low levels (Figure 3A). Thus, they were transfected 
with an empty vector (mock) or with a vector expressing a 
Myc-tagged human BMP7 cDNA to mirror the situation in 
rat and human primary PCCs (Figure 3A). Ectopic BMP7 
overexpression slightly increased PC12 proliferation rates 
(P < 0.01) (Figure 3E).
Figure 2: Expression of BMP7 in human PCC. A–D. IHC for BMP7 was performed on tissue microarrays using a human anti-
BMP7 antibody. After selection, 150 PCCs and 34 PGLs were scored. We only considered tumors for which both cores could be scored 
after IHC staining. Images were recorded and we show low (original magnification, × 40) and high (original magnification, × 400) power 
views of four different PCCs representative of the intensities of BMP7 staining (A,−; B,+; C,++; D,+++). E–H. BMP7 expression of the 
184 tumors was correlated with clinical variables, including (E) location (Extra-adrenal PCC = PGL; Adrenal PCC = Pheo), (F) tumor size 
(<35 mm; >8 mm), (G) genetic background (cluster 1; cluster2), and (H) malignancy (malignant; benign). n.s., not significant.
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MPC and MTT mouse PCC cell lines were found 
to have relatively high endogenous Bmp7 levels (Figure 
3B, 3C) and were therefore utilized for knockdown 
experiments. Similar to PC12 cells, MPC and MTT cells 
were found to express BMP receptors (Supplementary 
Figure S1). Because these cells were difficult to transfect, 
we generated lentiviral vectors expressing small hairpin 
(sh)RNA molecules directed against both mouse and rat 
Bmp7 gene together with the green fluorescent protein 
(GFP) to monitor infection efficiency (around 80%–90%, 
data not shown). Two sequences (#1.8 and #2.9) were 
originally cloned and tested in preliminary experiments 
that showed that GFP vector alone had no effect on cell 
proliferation, while both shBmp7 constructs decreased 
cell proliferation (Supplementary Figure S2A). Since 
sequence #2.9 reduced Bmp7 expression more efficiently 
(Supplementary Figure S2B), it was selected for further 
experiments.
We found that reduced endogenous Bmp7 expression 
decreased the proliferation of MPC (30% reduction; 
P < 0.05) and MTT (20% reduction; P < 0.05) cells 
(Figure 3F). Bmp7 knockdown in shBmp7-infected cells 
was confirmed by western blotting (Figure 3B, 3C). We 
then evaluated the potential tumorigenic role of Bmp7 in 
a more physiological system: primary cultures of MENX-
derived PCCs. We first confirmed that the tumor cells 
in vitro maintain the high Bmp7 expression seen in the 
primary tumors of origin (Figure 3D) and that they express 
BMP receptors (Supplementary Figure S1). Preliminary 
experiments showed that shBmp7 #2.9 lentiviral vector 
was the most effective vector also in this experimental 
system and was further employed (Supplementary Figure 
S2C, S2D). Then, PCC cells from three mutant rats were 
dispersed in culture plates and infected with shBmp7-GFP 
or GFP-only lentiviral vectors. Concomitantly, with a 
reduction of Bmp7 expression (Figure 3D), we observed 
a significant decrease in primary cell viability upon 
infection with shBmp7-vector (35%–45% reduction versus 
control GFP-vector) (Figure 3G). Therefore, autocrine 
Bmp7 signaling plays a role in sustaining the survival of 
rat primary adrenomedullary tumor cells.
BMP7 enhances migration and invasion of 
PCC cells
Next, we investigated whether BMP7 promotes 
cell migration and/or invasion of PCC cells. BMP7- 
or empty-vector-transfected PC12 cells were used 
Figure 3: Bmp7 promotes proliferation of PCC cells in vitro. A. We transfected PC12 cells with a Myc-BMP7 plasmid, and 
24 h later cells were analyzed by western blotting using a specific anti-Myc antibody. B. MPC, C. MTT and D. primary rat tumor (P.C.) 
cells were infected with lentiviral vectors containing shBMP7-GFP (#2.9) or GFP alone. Western blotting was performed 72 h later using 
the rat anti-BMP7 antibody. α-Tubulin was used as loading control. E. PC12 cells were transfected with the BMP7 plasmid (BMP7) or 
with the mock vector (Mock) and proliferation was assessed 24 h later using the WST-1 assay. Data were analyzed independently with six 
technical replicates each, and are expressed as the mean ± SD. Proliferation was normalized against the values of mock transfected cells 
arbitrarily set to 100%. **, P < 0.01. F. MPC and MTT cells were infected as in B and C, and 72 h later we assessed proliferation using the 
WST-1 assay. Data were analyzed independently with six technical replicates each, and are expressed as the mean ± SD. Proliferation was 
normalized against the values of GFP-infected cells arbitrarily set to 100%. *, P < 0.05. G. Primary cells (P.C.) were infected as in D and cell 
viability was measured 72 h after infection. The average of three independent cultures from three mutant rats (8 months of age) is shown. 
Proliferation was normalized against the values of GFP-infected cells which were arbitrarily set to 100%. **, P < 0.01.
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for migration assays employing a Boyden chamber. 
Elevated BMP7 expression stimulated PC12 cell 
migration (1.8-fold that of empty vector-transfected 
cells) (Figure 4A, 4C). Invasion assays through a 
Matrigel basement membrane matrix were conducted 
in parallel. BMP7-transfected PC12 cells displayed 
higher invasion potential (2.8-fold) than empty-vector-
transfected cells (P < 0.01) (Figure 4B, 4E). Similar 
experiments conducted on MPC cells showed that 
Bmp7 downregulation by the shBmp7-containing vector 
reduced their migration and invasion potential by up 
to 65% (P < 0.001) and 70% (P < 0.001), respectively, 
compared with GFP-vector-infected cells (Figure 4A, 
4B, 4D, 4F). Similarly, migration (average 70% 
reduction; P < 0.001) and invasion (80%; P < 0.001) 
of MTT cells were reduced upon Bmp7 knockdown 
(Figure 4A, 4B, 4D, 4F).
Thus, high endogenous Bmp7 levels promote 
proliferation, but especially migration and invasion (i.e., 
the metastatic potential) of PCC cells.
BMP7 pathway activation increases integrin 
β1 expression
Given that BMP7 overexpression stimulates PCC 
cell migration/invasion, we decided to comprehend the 
involved molecular mechanisms. We focused on integrins, 
cell surface receptors that are critical regulators of cell 
motility [31]. Among the integrin subunits, integrin β1 
has been associated with the progression of several cancer 
types. As it was found expressed in all three PCC cell 
lines (data not shown), it was selected for further studies. 
If integrin β1 was involved in Bmp7-mediated increase in 
PC12 cell migration/invasion, we expected it to be induced 
by activated Bmp7 signaling. Indeed, ectopic BMP7 
overexpression increased not only PC12 cell migration/
invasion (Figure 4A, 4B) but also the amount of integrin 
β1 (Figure 5A). As assessed by IF, BMP7 up-regulation 
enhanced integrin β1 expression in transfected and nearby 
un-transfected cells, consistent with a paracrine signaling 
mechanism. In contrast, empty-vector-transfected cells 
Figure 4: Bmp7 enhances migration and invasion of PCC cells in vitro. We transfected PC12 cells with a Myc-BMP7 plasmid 
and 24 h later A, C. migration and B, E. invasion were assessed. MPC and MTT cells were infected with lentiviral vectors containing 
shBmp7-GFP or GFP alone, and 72 h later we assessed A, D. migration and B, F. invasion. The percentage of cells that migrated or invaded 
was normalized against the values of mock transfected cells or of GFP-infected cells arbitrarily set to 100%. The experiment was performed 
two times with three technical replicates with similar results. Five random fields of each test at ×400 magnification were counted (±SD). 
**, P < 0.01; ***, P < 0.001.
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exhibited extremely faint staining for integrin β1 by both 
IF and western blotting (Figure 5A). PC12 cells were 
also treated with recombinant human (rh) BMP7, which 
up-regulated the canonical downstream pathways (i.e., 
P-Smad1/5/8) similar to BMP7 overexpression (Figure 5B). 
Following rhBMP7 addition to the culture media, integrin 
β1 expression was assessed at different time points and was 
found to be induced 15 min post-stimulation (Figure 5C). 
To verify that integrin β1 mediates the BMP7-dependent 
increase in cell migration and invasion, PC12 cells were 
co-transfected with Myc-BMP7 and scrambled siRNA 
oligos, or with Myc-BMP7 and siRNA oligos against the 
Figure 5: Downstream BMP7 signaling in PCC cells. A. PC12 cells were transfected with a BMP7-containing (BMP7) or an empty 
(mock) vector. Twenty-four h post transfection IF was performed using specific antibodies targeting integrin β1 (1:400) or BMP7 (1:100). 
Cell nuclei were counterstained with DAPI. In parallel, the expression of integrin β1 and BMP7 proteins was determined by western blotting 
using specific antibodies. α-Tubulin was used as loading control. B. PC12 cells were either transfected (txBMP7) with a Myc-BMP7 plasmid 
or treated with 100 ng/mL recombinant human BMP7 (rhBMP7). After 24 h, cells were collected and analyzed by western blotting using 
antibodies against P-Smad1/5/8 and Smad1. α-Tubulin was used as a loading control. C. PC12 cells were treated with rhBMP7 for 5, 15, 30, 
45, or 60 min. Western blot analysis was performed using specific antibodies raised against integrin β1, AKT and P-AKT. α-Tubulin was used 
as loading control. D. We co-transfected PC12 cells with BMP7 and scr-siRNA or siRNA-Itgb1 and 24 h later proliferation, migration and 
invasion were assessed. Values for cells with knockdown of Itgb1 were normalized against the values of scr-siRNA-transfected cells arbitrarily 
set to 100%. The experiments were performed two times with three technical replicates with similar results. For proliferation, the average of 
the 2 experiments is shown. For migration/invasion, five random fields of each test at × 400 magnification were counted (average ± SD). **, 
P < 0.01; ***, P < 0.001. In parallel, the levels of BMP7, integrin β1, P-AKT and AKT were assessed in the transfected cells by western blotting 
with specific antibodies as described above. α-Tubulin was used as a loading control. (Continued )
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Itgb1 gene (siItgb1) encoding integrin β1. Itgb1 silencing 
significantly reduced PC12 cell proliferation, migration and 
invasion capacity (Figure 5D). Efficient Itgb1 knockdown 
was confirmed by western blotting (Figure 5D).
Similar to integrin β1, P-AKT rapidly increased 
in rhBMP7-treated PC12 cells (Figure 5C). Integrin β1 
is regulated by PI3K/AKT/mTOR signaling in other 
cancers [32, 33]. Therefore, we investigated whether this 
also occurs in PCC. Upon incubation with the selective 
pan-AKT kinase inhibitor GSK690693, integrin β1 level 
decreased in PC12 cells with BMP7 overexpression 
(Figure 5E), consistent with a role for AKT in modulating 
integrin β1 expression. In PC12 cells, as in other cancer 
cells [34], P-AKT did not decrease following GSK690693 
treatment because of the blockade of a negative feedback 
loop downstream of AKT.
As no data were available on integrin β1 expression 
in human PCCs, 10 tumors with enough frozen material 
were analyzed by western blotting and compared with 
normal adrenal medulla. Samples were also probed for 
BMP7 and P-AKT expression. The results revealed 
that integrin β1 is expressed in PCCs; its level tends to 
correlate with that of BMP7 (Figure 5F). Primary PCCs 
having high BMP7 and integrin β1 levels mostly showed 
also elevated P-AKT.
BMP signaling inhibition suppresses PCC cell 
proliferation and promotes apoptosis
Due to its involvement in human cancers, the 
BMP pathway has been considered for therapeutic 
intervention, and small-molecule BMP antagonists are 
being evaluated in preclinical studies. Among them, 
DMH1, a second-generation analog of dorsomorphin, 
highly selectively inhibits BMP type I receptors 
(BMPR-I), but no other off-target receptors [35]. To 
verify whether blocking BMP receptor signaling might 
be a potential strategy for targeted therapy of PCC, 
we treated MTT cells (high endogenous Bmp7 levels) 
with DMH1 and then assessed cell proliferation and 
migration. DMH1 treatment significantly suppressed 
MTT cell proliferation in a dose- and time-dependent 
manner (Figure 6A), and even more strongly inhibited 
cell migration (Figure 6B). Concomitantly, we observed 
a dose-dependent downregulation of the expression of 
P-Smad1/5/8 and integrin β1, both readouts of active 
BMP signaling in PCC cells, as well as of P-AKT in 
DMH1-treated MTT cells (Figure 6C).
Next, we determined the effect of DMH1 on rat 
primary PCC cells (high Bmp7 expression). Independent 
cultures from 5 affected rats were incubated with different 
DMH1 concentrations, and this resulted in a strong 
decrease in cell viability (Figure 6D).
In conclusion, a novel small-molecule BMP 
antagonist elicits anti-proliferative and anti-migratory 
responses in PCC cells with active BMP signaling in vitro.
Tumors expressing high Bmp7 levels respond 
well to PI3K inhibition in vivo
The increase in P-AKT following either BMP7 gene 
transfection or rhBMP7 treatment suggests that BMP7 
signaling occurs through the PI3K/AKT/mTOR pathway in 
PCC cells. Given our data on the high BMP7 levels in PCCs 
and on its pro-oncogenic function, targeting the PI3K pathway 
may represent an effective therapeutic strategy for treating 
these tumors. To test this hypothesis, we employed MENX 
rats as a prototypic in vivo model of endogenous PCCs 
having elevated BMP7 expression and an activated PI3K 
pathway [36]. We previously reported that NVP-BEZ235, 
a dual PI3K-mTOR inhibitor, has antitumor activity against 
primary PCC cultures from MENX rats in vitro [36]. Here 
we daily administered NVP-BEZ235 (n = 4) or PEG vehicle 
(n = 4) to MENX-affected rats by oral gavage for 2 weeks. 
Figure 5:  (Continued ) Downstream BMP7 signaling in PCC cells. E. PC12 cells were treated with the indicated 
concentrations of the P-AKT inhibitor GSK690693 and western blot analysis was performed 24 h later to determine the expression of 
BMP7, integrin β1, P-AKT, and AKT. α-Tubulin was used as a loading control. F. Expression of BMP7, integrin β1, and P-AKT in 10 
human primary PCCs and one human normal medulla (cont.) was assessed by western blotting using specific antibodies. α-Tubulin was 
used as a loading control.
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Post-treatment, we observed a reduction of both P-S6 
(Figure 7A, 7B), a downstream effector of mTOR, and 
integrin β1 (Figure 7C, 7D), readout of BMP signaling, 
in tumors following NVP-BEZ235 but not vehicle 
administration, thereby confirming BMP/PI3K pathway 
blockade. Concomitantly, PCCs of drug-treated rats displayed 
a significant reduction in proliferation (Ki67 staining) and 
increase in apoptosis (Annexin V and active caspase 3 
staining) (Figure 7F–7I). These findings in vivo recapitulate 
the signaling pathway that we identified in PCC cells 
in vitro, wherein active BMP7 signaling induces integrin β1 
expression through PI3K/AKT/mTOR pathway activation. 
Moreover, they demonstrate that targeting the PI3K signaling 
cascade evokes antitumor effects in PCCs with active BMP 
signaling in vivo.
DISCUSSION
The molecular mechanisms accompanying 
sporadic PCC remain largely undefined, thereby 
hampering the identification of novel therapeutic targets 
for this occasionally aggressive and malignant tumor. 
In this study, we show that BMP7 is highly expressed 
in PCC, where it promotes pro-oncogenic features 
Figure 6: Effect of DMH1 on BMP downstream signaling and PCC cell growth. A. MTT cells were treated with DMH1 (3 μM 
or 5 μM) or with DMSO vehicle. Proliferation was assessed at the indicated times by the WST-1 assay. The experiments were performed 
two times with six technical replicates each, and are expressed as the mean ± SD. The values are normalized against those of DMSO-
treated cells set to 100%. ***, P < 0.001. B. MTT cells treated as in A for 24 h were used for migration assays as indicated in Figure 4. 
The percentage of cells that migrated was normalized against the values of DMSO-treated cells arbitrarily set to 100%. The experiment 
was performed two times with three technical replicates with similar results. Five random fields of each test at ×400 magnification were 
counted (±SD). *, P < 0.05; **, P < 0.01. C. MTT cells were treated with DMH1 (3 μM or 5 μM) or with DMSO vehicle for 24 h. Proteins 
were then collected and probed for the expression of integrin β1, P-Smad1/5/8, Smad1, P-AKT and AKT. α-Tubulin was used as a loading 
control. D. Rat primary tumor cells were treated with DMH1 (3 μM and 5 μM) or DMSO for 72 h and cell viability was assessed using the 
WST-1 assay. Shown is the average of five independent cultures from five mutant rats (8 months of age). The values are normalized against 
those of DMSO-treated cells set to 100%. Data were analyzed independently with six technical replicates each and are expressed as the 
mean ± SD. ***, P < 0.001.
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through autocrine- and paracrine-mediated activation of 
PI3K/AKT/mTOR signaling cascade and of integrin β1 
expression. We demonstrated that this knowledge may be 
exploited for therapeutic purposes in proof-of-principle 
studies using in vitro and in vivo PCC models.
We previously reported that BMP7 is overexpressed 
in human PCC [14]. In this study, we demonstrate that the 
BMP7 protein is highly expressed in 72% of human tumors 
and it associates with tumor location (more frequently 
elevated in PGLs than in PCCs) and tumor size (higher in 
large PCCs). Of note, tumor size positively correlates with a 
higher malignancy risk for PCC [6], and, although data are 
not always consistent, an increased malignancy rate has been 
reported for PGLs compared with PCCs [6]. In our patient 
cohort, nine of 11 malignant tumors (82%) had high BMP7 
expression. As BMP7 has already been shown to be a marker 
of tumor progression and metastases development in breast 
and esophageal cancers [25, 37], it is worth further exploring 
the potential of BMP7 as a marker of malignant behavior by 
analyzing additional malignant PCC cases for its expression.
Our understanding of the contribution of BMP 
signaling to cancer biology remains limited. Although 
activation of BMP-mediated pathways inhibits cell 
growth and induces apoptosis in various cancer cell 
types, it can also be implicated in increasing metastatic 
potential and tumor angiogenesis in other tumor types 
[25, 26, 38]. To date, the contribution of BMP7 signaling 
to PCC pathogenesis has not been addressed. By 
manipulating endogenous Bmp7 levels in PCC cell lines 
(overexpression and knockdown) and in primary rat tumor 
cells (knockdown), we could demonstrate that endogenous 
Bmp7 overexpression promotes oncogenic features in these 
cells. Specifically, high Bmp7 gene expression promoted 
the proliferation and potently induced the migration and 
invasion of PC12, MPC, and MTT cells. This situation 
is reminiscent of what has been reported about activation 
of BMP2- and BMP4-dependent pathways in other tumor 
types [39, 40]. Moreover, shRNA-mediated Bmp7 gene 
silencing reduced the viability of rat primary PCC cells, 
suggesting that in this experimental system Bmp7 sustains 
Figure 7: Ex vivo analysis of rat PCCs following placebo or NVP-BEZ235 treatment. MENX-affected rats (n = 4) were 
treated with a dual PI3K/mTOR inhibitor, NVP-BEZ235, or with PEG vehicle (n = 4) by oral gavage for 2 weeks then adrenal glands 
were collected. A–I. IF or IHC on tissues collected from the rats was performed using specific antibodies raised against P-S6, integrin β1, 
Ki67, Annexin V or active-caspase3. For IHC, haematoxylin was used as counterstaining, while for IF, cell nuclei were counterstained with 
DAPI. Original magnification: ×400. Scale bars: 20 μM.
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cell survival. Thus, similar to what has been reported for 
lung cancer [41], melanoma [42] and, albeit controversial, 
for breast cancer [25], BMP7 exerts a tumor-promoting 
action in PCC.
Because BMP7 strongly increases the motility and 
invasion of PCC cells, we investigated the molecular 
mechanisms that might mediate these effects. We 
focused on integrin β1: a major cell adhesion molecule in 
mammalian cells, extensively associated with the motility 
and invasion of tumor cells, and expressed in all PCC cell 
lines. No data were available up to now on integrin β1 
involvement in PCC. We observed that both ectopic Bmp7 
overexpression and treatment with rhBMP7 associate with 
enhanced integrin β1 expression in PC12 cells, whereas 
selective blockade of BMP signaling by DMH1 causes a 
drastic reduction in integrin β1 expression in MTT cells. 
Knockdown of Itgb1 (integrin β1) suppresses BMP7-
mediated increase in proliferation, migration and invasion 
of PC12 cells. These findings provide experimental 
evidence to support the functional link between the BMP 
pathway and integrin β1. Moreover, analysis of human 
primary PCCs revealed for the first time that integrin β1 
is highly expressed in these tumors and its amount tends 
to correlate with that of BMP7. In breast cancer cells, it 
has been reported that BMP7 inhibits TGFbeta-induced 
invasion via inhibition of integrin β3 [43], again attesting 
to the cell-type dependent effect of BMP7 signaling. In 
conclusion, we identified integrin β1 as a downstream 
target of BMP-dependent signaling in PCC and as a tumor 
progression driver.
Human primary PCCs are characterized by the 
hyperactivation of the PI3K/AKT pathway [1, 44]. Here 
we report that over half of PCCs are characterized by high 
BMP7 expression, and that active BMP-dependent pathways 
increase P-AKT levels in PCC cells. Thus, it is tempting to 
speculate that the PI3K pathway activation observed in PCCs 
might be in part due to BMP7 expression upregulation and 
the triggering of a cell autonomous stimulatory pathway. 
Mechanistically, we postulate that BMP7 signaling activates 
the PI3K/AKT/mTOR pathway, which in turn leads to the 
up-regulation of integrin β1. Indeed, inhibiting AKT or PI3K/
mTOR activities in the context of active BMP7-mediated 
pathways reduced integrin β1 expression in PCC both 
in vitro and in vivo. Integrin β1 up-regulation by the activated 
PI3K/AKT pathway has been also documented in other 
cancers, including breast [32] and prostate carcinomas [45], 
where it accounts for enhanced cell motility and invasion.
Our data uncover downstream effectors of 
active BMP signaling that could be the target of novel 
therapeutic strategies for PCC. To verify this, we 
investigated whether the inhibition of the PI3K/AKT/
mTOR pathway is effective against PCCs expressing 
high levels of BMP7. Specifically, we exploited our 
MENX rat model to study the response of endogenous 
PCCs to a dual PI3K/mTOR inhibitor (NVP-BEZ235) 
that is bioavailable and in clinical trials. NVP-BEZ235 
displays antitumor effects against PCC cell lines and 
primary rat PCC cells in vitro [36, 46]. Here, ex vivo 
analysis of the rat tumors confirmed that NVP-BEZ235 
inhibits BMP and PI3K/mTOR signaling, reduces 
integrin β1 expression and cell proliferation, and induces 
cell death. Collectively, these data support our hypothesis 
that targeting the PI3K signaling cascade holds promise 
in PCC treatment as a paradigm of tumors with active 
BMP7-mediated signaling. They also suggest that 
BMP7 might be a potential predictor of response to such 
antitumor agents.
To date, everolimus (rapamycin analogue) was 
evaluated in a few patients with progressive/malignant 
PCCs, but exhibited low efficacy [10, 11]. This lack of 
tumor control could be due to the activation of a feedback 
loop reactivating AKT signaling upstream of mTOR, a 
well-documented mechanism of resistance to rapamycin 
and its analogues in various human cancers [47, 48]. To 
escape the feedback resistance, compounds able to inhibit 
both mTOR and the upstream PI3K kinase were generated, 
including NVP-BEZ235 [49]. Our preclinical in vivo trial 
provides the rationale for targeting the PI3K pathway 
in patients with progressive/inoperable PCCs using 
dual PI3K/mTOR inhibitors instead of single-molecule 
inhibitors.
While drugs inhibiting the PI3K pathway have 
reached the clinical trial stage or are already approved 
for treatment, BMP antagonists are still in preclinical 
development, but may be available for clinical applications 
in the future. Among them is DMH1, the most selective 
small molecule inhibitor of BMP receptor signaling 
currently available [35]. DMH1 inhibits the intracellular 
kinase domains of BMPR-I molecules such as ALK1 
(activing receptor-like kinase 1), ALK2, ALK3/BMPR-
IA and ALK6/BMPR-IB, but does not inhibit ALK4 and 
ALK5, nor other kinases such as AMP-activated kinase, 
VEGF (vascular endothelial growth factor) receptor type 
2 and PDGF (platelet-derived growth factor) receptor 
β [35, 50]. DMH1 has recently been shown to inhibit 
breast-to-lung metastases and to reduce primary growth 
of mammary carcinomas in mice [50], and to suppress the 
tumor growth of a human lung cancer xenograft model 
[51]. Our data of an antitumor effect elicited by DMH1 in 
PCC cells hold great promise for future targeted therapies 
of these tumors.
In summary, our work identifies BMP7 as a novel 
pro-oncogenic factor in PCC and provides leads for 
novel therapeutic approaches against PCCs targeting 
downstream effectors of BMP7-mediated signaling.
MATERIALS AND METHODS
Human pheochromocytoma samples
This study was approved by the Ethics Committees 
of the Universities of Munich, Tübingen, and Florence; 
Oncotarget39122www.impactjournals.com/oncotarget
informed written consent was obtained from all patients. 
PCC tissues were snap-frozen after surgery and stored at 
−80°C until required. Frozen normal adrenals and tumors 
were also provided by the Imperial College Healthcare 
NHS Trust Tissue Bank (Project R13041).
Tissue microarrays (TMAs) containing 208 human 
adrenal tumors (166 PCCs, 42 PGLs) and control tissues 
were obtained from the ENS@T (European Network for 
the Study of Adrenal Tumors) and previously described 
[52]. For each tumor, two different areas (cores) were 
selected for the arrays.
Rat tissue and plasma samples
Adrenals of age-matched wild-type and MENX-
affected rats were fixed in 4% buffered formalin and 
embedded in paraffin. Histological examination confirmed 
the diagnosis of PCC. Three-micrometer sections were used 
for IHC or IF. Plasma from age-matched wild-type and 
MENX-affected rats was obtained at autopsy and stored at 
−80°C. Plasma Bmp7 levels were measured with an ELISA-
KIT obtained from USCN Life Science Inc. (Wuhan, China).
Cell culture, treatments, and assays
Mouse PCC cells, MPC 4/30 PRR [53], derived 
from a heterozygous Nf1-mutant mouse PCC, and its 
more aggressive derivative MTT [54] cells, were kindly 
provided by Dr. Karel Pacak (NIH, Bethesda, Maryland, 
USA) and cultured in DMEM medium (Sigma, Hamburg, 
Germany) containing 10-ml fetal bovine serum (FBS) and 
1% (v/v) penicillin/streptomycin at 37°C in a 5% CO2 
atmosphere. Rat PC12 cells were purchased from LGC 
Standards (Wesel, Germany) and cultivated, following 
manufacturer’s instructions. All cells were routinely 
tested for mycoplasma and found free of contamination. 
Moreover, they were maintained in culture for maximum 5 
passages after thawing. Primary PCC cells from MENX 
mutant rats were established and cultivated as previously 
reported [36].
PC12 cells were transfected with plasmid DNA 
as described [17], or with 200 pmol of scrambled (ON 
TARGETplus Non-targeting siRNA, Dharmacon, 
Lafayette, CO, USA) or pooled siRNA against rat 
Itgb1 gene (ON-TARGET plus SMART pool siRNA, 
Dharmacon) by Amaxa 4D-Nucleofector (Lonza) follo-
wing the manufacturer’s instruction. For infections, 
MPC, MTT, and primary tumor cells were plated on 
96-well plates and were infected with lentiviral vectors 
expressing either green fluorescence protein (GFP) 
alone (pGreenPuro #SI505A-1-SBI, BioCat, Heidelberg, 
Germany) or GFP and shRNA against BMP7. Virus 
productions were performed as published [55] and 
infections slightly adjusted to the described protocol. 
Two different shBmp7 sequences were originally 
cloned into a pGreenPuro lentiviral vector: #1.8: FW 
AGGCCTGATTGGACGGCAT; #2.9: FW 5′-CGGGA 
GAUGCAGCGGGAAA-3′.
WST-1 colorimetric assay (Roche, Mannheim, 
Germany) for cell viability was performed 72 h after 
infection according to the manufacturer’s recommendations.
Protein extraction and western blotting
Cells were harvested after treatment with rhBMP7 
transfection or infection at specific timepoints. Total 
proteins were extracted from cells or frozen tissues, and 
western blotting was performed as previously reported 
[56]. The primary antibodies used are: human anti-BMP7 
(R&D Systems, USA; clone #164311; dilution 1:1000); 
rat anti-Bmp7 (#4693, 1:100), P-Smad1/5/8 (#9511, 
1:50), Smad1 (#5753; 1:500), AKT (#9272; 1:500) and 
P-AKT (#9271; 1:500) all from Cell Signaling Technology 
(Danvers MA, USA); integrin β1 (Abcam, Cambridge, 
UK; #EP1041Y; dilution 1:500); anti-Myc tag (Clontech, 
St-Germain-en-Laye, France; #631206; dilution 1:500), 
α-Tubulin (Sigma-Aldrich, Hamburg, Germany; #T5168; 
dilution 1:1000). Western blotting experiments from 
biological replicates showed similar expression data, 
attesting to the reproducibility of the results.
IHC and IF
IHC was performed on an automated immunostainer 
(Ventana Medical Systems, Tucson, AZ) as previously 
described [57]. The primary antibodies used are: rat anti-
BMP7 antibody (see above; dilution 1:100), human anti-
BMP7 (see above; dilution 1:1000), anti-P-S6 antibody 
(Cell Signaling Technology; #2211; 1:500). Primary 
antibodies were diluted in Dako REALTM antibody 
diluent (Dako, Hamburg, Germany). Haematoxylin was 
used as counterstaining. Positive controls were included 
in each batch. TMAs were scored for BMP7 expression 
using a semi-quantitative method taking into account the 
staining intensity: − (negative), + (mild), ++ (moderate), 
and +++ (strong). Slides were scored using a double-blind 
method by two independent observers; the percentage of 
discrepancies was below 3%. We only considered tumors 
for which both cores could be scored after IHC staining 
processes (inclusion criteria). Images were recorded 
using a Hitachi camera HW/C20 installed in a Zeiss 
Axioplan microscope with Intellicam software (Carl Zeiss 
MicroImaging, Göttingen, Germany).
For IF, we used primary antibodies against BMP7 
(see above), P-Smad1/5/8 (see above), integrin β1 
(1:200), Ki67 (BD Biosciences, Heidelberg, Germany; 
#550609; 1:100), Annexin V (Abcam; ab14196; 1:100) or 
active-caspase3 (Cell Signaling; #9664; 1:200). Cell nuclei 
were counterstained with DAPI. Secondary anti-mouse 
Alexa Fluor® 555 Conjugate (Cell Signaling), secon-
dary anti-rabbit FITC-conjugated antibody (Invitrogen, 
Darmstadt, Germany) were used as reported [58]. Sections 
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were analyzed with a Zeiss Axiovert 200 epifluorescence 
microscope including Apotome unit (Carl Zeiss).
Migration and invasion assays
Chemomigration assays were performed using 
24-well plates with uncoated polycarbonate membrane 
inserts (BD BioCoat™, BD, Heidelberg, Germany). Cells 
were transfected with Myc-BMP7 or empty vector, and 
trypsinized and collected 24 h later in a medium containing 
0.02% FBS and 0.1% horse serum (HS). A total of 50000 
cells (PC12) or 100000 cells (MPC/MTT) were added 
onto the insert. The lower well was filled with a medium 
complemented with 2.5% FBS and 15% HS. Migrated 
cells were fixed 24 h later in 100% methanol and stained 
with 1.5% (w/v) toluidine blue in water. MPC and MTT 
cells were infected for Bmp7 knockdown and the same 
procedure as above was employed after 72 h. Invasion 
assays were performed with matrigel-coated polycarbonate 
membrane inserts (BD BioCoat™, BD) according to the 
manufacturer’s recommendations. We plated 75000 cells 
(PC12) or 150000 cells (MPC/MTT) for these assays.
Quantitative TaqMan RT-PCR
RNA was extracted using RNeasy Mini Kit 
(Qiagen, Hilden, Germany) following the manufacturer’s 
instructions. Quantitative RT-PCR was performed 
using TaqMan inventoried primers and probes (Applied 
Biosystem, CA, USA) for the indicated genes, following 
previously reported protocols [14].
RT-PCR analysis of Bmp receptor genes
Semiquantitative RT-PCR was performed for 
Bmp receptor transcripts using RNA extracted from 
microdissected adrenomedullary cells of the tissue 
samples or MPC, MTT, PC12, and primary cells of rat 
PCCs. Primers used for semi-quantitative analysis are 
described in Supplementary Table S1. Conditions for the 
RT-PCR reaction were as previously reported [14].
In vivo treatment
This study was approved by the ethics committee 
on animal research of the government of Upper Bavaria, 
Germany. MENX-affected rats were maintained as 
previously reported [12] in agreement with the procedures 
approved by the Helmholtz Zentrum München, by 
the Technische Universität München, and by the local 
government authorities.
NVP-BEZ235 was kindly supplied by Novartis 
Pharma. In preliminary experiments, various doses of NVP-
BEZ235 were tested in MENX rats, as reported [58], and the 
dose of 20 mg/Kg was selected. MENX-affected rats at 7–8 
months of age (with adrenal tumors but still in good general 
health) were treated for 14 days with NVP-BEZ235 (20 mg/
kg) or placebo (PEG) administered daily per oral gavage. At 
the end of the treatment, adrenal glands were collected for 
IHC and IF of relevant markers.
Statistical analyzes
Study endpoints from the in vitro experiments, 
including cell proliferation, migration, and invasion, as 
well as primary cell viability are summarized using bar 
graphs with means ± SD. A paired two-tailed Student’s 
t test was used to detect significance between two series 
of data, and P < 0.05 was considered significant. For 
TMA results, the staining results were compared with the 
clinicopathological features and correlations were assessed 
using Fisher’s exact test.
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